All the below link and tweets are in English.
取り急ぎ以下貼っておきます。
UK Vol.170 (pharmaceutical corporations: GlaxoSmithKline)
上記リンク内に無い本日までのツイート
Today we, together with @Sanofi and @Gavi, announced a Statement of Intent to make available 200m doses of our Sanofi/GSK co-developed #COVID19 #vaccine to the COVAX Facility, if successful in clinical trials. Learn more: https://t.co/OYGgP1QpVk pic.twitter.com/pnKYUy15Dq
— GSK (@GSK) October 28, 2020
Our intent to supply the COVAX Facility (led by @gavi and @WHO) with 200m doses of our co-developed #COVID19 #vaccine, if successful in clinical trials, is key to ensuring equitable access for every country in the world and protecting those most at risk. https://t.co/CcPiEsruRN pic.twitter.com/ufnuOfxVJ3
— GSK (@GSK) October 28, 2020
Our recent announcement that we will make available 200m doses of the #vaccine we’re co-developing with @Sanofi to COVAX, could, if successful in clinical trials, be a key milestone to helping end this #COVID19 #pandemic. https://t.co/aje70UKtQz
— GSK (@GSK) October 29, 2020
Interesting insights from global experts on #pandemic prevention and preparedness, including the role of #vaccines, as we learn from #COVID19. (Subscription may be required). https://t.co/AgxJLWB3rA
— GSK (@GSK) October 30, 2020
We are proud to join @ScienceMagazine Top 20 Employers. Testament to bringing together great science, new tech, and outstanding people. @ScienceCareers #Innovation #SCTopEmployer pic.twitter.com/VzLEyNRS9I
— GSK (@GSK) October 31, 2020
Thanks to our own @EstOdek for highlighting what needs to happen so #BIPOC are represented, visible & celebrated in #Science. We’re inspired by her to continue building an inclusive environment where all scientists feel valued & can bring their best and authentic selves to work! https://t.co/5QdufNCgm7
— GSK (@GSK) October 30, 2020
Collaboration in the wake of #COVID requires trust. Our CSO Hal Barron talks about how our partnership with @Vir_Biotech came together in 18 days and why focus on critical issues is key in the @WSJ article: https://t.co/M8aC4lyR4a pic.twitter.com/2YkaIyu0pP
— GSK (@GSK) October 24, 2020
Our CSO Hal Barron and President of Global Vaccines Roger Conner spoke with @joewalkerWSJ about how #COVID19 is ushering in a new era of industry collaboration. https://t.co/hkKwkyLzEb
— GSK (@GSK) October 24, 2020
#DYK Most adults in the US aren't vaccinated against #HepA? #Hepatitis A can be transmitted through close contact w/ an infected person or through contaminated food or water. Talk to your doctor about vaccination.
Visit ➡️ https://t.co/cEV0x0F39t#LiverAwarenessMonth #NOhep pic.twitter.com/MVI3DVzUZO— GSK US (@GSKUS) October 27, 2020
We’re supporting the voice of the patient by working together to eliminate access barriers at the Alliance for Health Policy, Voice of the Patient Health Summit 2020. #AHPSummit20 #patientvoice https://t.co/vki0yDOUVo
— GSK US (@GSKUS) October 26, 2020
Sanofi and @GSK have signed a Statement of Intent with the @gavi @WHO @CEPIvaccines #COVAX facility to secure the distribution of our #COVID19 vaccine worldwide: https://t.co/NB1oald3wH#SanofiActs pic.twitter.com/BXD2sLoh0h
— Sanofi (@sanofi) October 28, 2020
This year has shown unprecedented collaboration across our industry. Congratulations, John Shiver, SVP of R&D, @sanofipasteur, in partnership with @GSK, on being named one of @FiercePharma’s most influential people in the fight against #COVID19. https://t.co/I458tte4iO
— Sanofi US (@SanofiUS) October 27, 2020
Today we are proud to announce our intent to supply 200 million doses of our adjuvanted recombinant protein #COVID19 vaccine, if approved to #COVAX alongside @GSK. This will help offer timely and cost-effective access to vaccines worldwide.@gavi Learn more https://t.co/uRDSulc3zb pic.twitter.com/JrWpcOrGqu
— Sanofi Pasteur (@sanofipasteur) October 28, 2020
We are extremely proud of John Shiver, Senior Vice President of Vaccines Global R&D, for being named by @FiercePharma as one of the most influential people in the fight against #COVID19, in partnership with @GSK. https://t.co/LAIf0GT1Pr
— Sanofi Pasteur (@sanofipasteur) October 27, 2020
We’re pleased to announce we have signed a Statement of Intent to procure 200 million doses of the @Sanofi and @GSK #COVID19 vaccine candidate for the #COVAX Facility! https://t.co/4Pv6BtXFtn @CEPIvaccines @WHO
— Gavi, the Vaccine Alliance (@gavi) October 28, 2020
Very pleased that @Gavi has signed a Statement of Intent with @Sanofi and @GSK to provide 200 million doses of their adjuvanted recombinant protein #COVID19 vaccine to the #COVAX Facility! https://t.co/pUO6ntVnLR
— Seth Berkley (@GaviSeth) October 28, 2020
Thank you @sanofi for your partnership and commitment alongside @GSK to ensure that safe and effective #COVID19 vaccines reach those in greatest need around the world. Pleased to welcome your commitment to the #COVAX goal of equitable vaccine access. #OneWorldProtected https://t.co/QraLhRsyVZ
— Seth Berkley (@GaviSeth) October 28, 2020
Thank you @GSK for working with @Sanofi to help ensure the most at-risk groups, such as healthcare workers, have rapid access to doses of #COVID19 vaccines. I welcome your commitment to global health security! #OneWorldProtected https://t.co/DmS1X7Vwea
— Seth Berkley (@GaviSeth) October 28, 2020
https://twitter.com/scibus/status/1321454739364728834
https://twitter.com/MSF_access/status/1321890170808008706
https://twitter.com/MSF_access/status/1321935282971807744
MSF calling for transparency from pharmaceutical corporations around price, supply and distribution of the potential future #COVID19 vaccine @GSK @sanofipasteur https://t.co/bvbHBaHvsT
— Shailly Gupta (@Shaillytweeting) October 29, 2020
Pharmaceutical giant @GSK will attend this year’s China International Import Expo. So what's the latest from #GSK on developing a #COVID19 #vaccine? And What are the highlights of their new products and services this year? pic.twitter.com/LjTM34TvhI
— Frontline (@Frontlinestory) October 29, 2020
EU approves Zejula as monotherapy in ovarian cancer @GSK https://t.co/hwtquaFAOL pic.twitter.com/JZbY6VsktN
— The Pharma Letter (@ThePharmaLetter) October 30, 2020
Sanofi & GSK to supply 200m doses of their Covid-19 vaccine to global distribution scheme
Read it here: https://t.co/fiz2Tjk0vK @sanofi l @GSK l @gavi pic.twitter.com/cpmV0nOaXB
— EPM Magazine (@EPM_Magazine) October 29, 2020
https://twitter.com/UN_SPHS/status/1321745134149656576
COVID-19 Vaccine Update: Sanofi, GSK to Supply COVAX with 200 Million Doses of Coronavirus Vaccinehttps://t.co/mPLw6qMCC5#COVID19Vaccine @sanofi @GSK #COVAX
— LatestLY (@latestly) October 29, 2020
The CEO of SBC Member Organisation @GSK is optimistic that a COVID-19 vaccine could be widely available in 2021. Find out more here:https://t.co/HmZgQgjY3w #COVID19 #covidvaccine pic.twitter.com/nREQEZsV93
— StevenageBioscience (@SteBioCat) October 28, 2020
Partner of #DMTR pic.twitter.com/LZPuOiyZlS
— riddler (@riddler_smitb) October 28, 2020
News for #pharma #marketers: Thurs, Oct 29
– @Sanofi, @GSK give 200 million COVID-19 vaccine doses to Covax
– @Pfizer will not report coronavirus vaccine results this month
– Podcast: @Genentech’s Quita Highsmithhttps://t.co/W779ysMOAh— MM+M Magazine (@MMMnews) October 29, 2020
Dave Tudor and John Arthur of the Medicines Manufacturing Innovation Centre mark the start of construction of the MMIC today – exciting times for UK Life Sciences, manufacturing and Scotland! @Ivan_McKee @ukCPI @UniStrathclyde @GSK @AstraZeneca @scotent https://t.co/7LUCJl1Qpv pic.twitter.com/7zRN1fCmy5
— Life Sciences Scot (@LifeSciScot) October 26, 2020
White House “Vaccine Czar” Dr. Slaoui is using loopholes and working under a shady contract to skirt ethics laws that would require him to sell all his stock in COVID vaccine manufacturers. @RepKatiePorter and I want @GSA_OIG to investigate his contract.https://t.co/6EMTPBd9RN
— Elizabeth Warren (@SenWarren) October 30, 2020
https://twitter.com/TomDoddFCDO1/status/1321891577317511169
Construction has started on the Medicines Manufacturing Innovation Centre – a collaboration between Strathclyde, @ukCPI & industry partners @AstraZeneca & @GSK. The new centre will put Scotland at the cutting edge of advanced pharmaceutical manufacturing.https://t.co/4DJIQBQk3q pic.twitter.com/mdcz8iWBAm
— University of Strathclyde (@UniStrathclyde) October 28, 2020
Thanks to UCL for a charming virtual graduation ceremony @ucleastman @ucl_slms Thanks to @GSK and @basem_uk @PaedDentEastman @IanNeedleman for supporting Dr Julie Gallagher on her journey pic.twitter.com/kHemprO2oC
— Oral Health in Sport (@oralhealthsport) October 29, 2020
Get to know some of the #SCTopEmployers in #biotech #pharma and find job opportunities—Explore the 2020 Top Employer Profiles for @GSK, @Roche, and @pfizer:https://t.co/EsP0urWYqx pic.twitter.com/mR7pv1ZvEZ
— Science Careers (@ScienceCareers) October 30, 2020
Congrats @GSKUS @GSK ! pic.twitter.com/4kZMvS5V0Q
— Talend (@Talend) October 29, 2020
Congratulations to @CondeNast, in partnership with @tweetPHM on behalf of @GSK, for winning the Online Video or Film category for their work on “Well, Actually”!#DPIWeek2020 #FierceAwards #BeFierce pic.twitter.com/l0dZPLZJmx
— Digital Pharma (@DigitalPharma) October 28, 2020
Impressive presentation of Prof. Koen Kas, @kaskoen, at the @GSK meets Belgian University Event, talking about several #digital examples to turn sick care into #Healthcare! https://t.co/tWpJXVPQgc
— FlandersVaccine (@FlandersVaccine) October 27, 2020
Thank you @Amgen, @chemocentryxinc, @genentech, @GSK and @sanguinebio for sponsoring our Newly Diagnosed Patient conference happening this Saturday! Come see for yourself how their support is already giving vasculitis patients a better quality of life. pic.twitter.com/LsUrh5Y9Ar
— Vasculitis Foundation (@VasculitisFound) October 29, 2020
500 followers up! Shout out to our amazing @AI4VBH industry partners – thank you for all support so far!@ainostics @Biotronics3D @CydarMedical @GEHealthcare @innersightlabs @KheironMedical @MiradaMedical @NetAppUK @nvidia @PerspectumGroup @SiemensHealth @GSK pic.twitter.com/RfPYGgQzVe
— London AI Centre for Value Based Healthcare (@AI4VBH) October 28, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
.@GSK and Daiichi Sankyo JV submits NDA for candidate #shingles vaccine in Japan https://t.co/rtg3TBFhCh pic.twitter.com/VJ1D4woI6R
— Pharma Tech Focus (@PharmaTechFocus) April 21, 2017
Anglo-Japanese JV announces Shingrix submission in Japan https://t.co/97zsKYDTBA #pharma @GSK @DaiichiSankyo @DaiichiSankyoJP
— The Pharma Letter (@ThePharmaLetter) April 19, 2017
Our president & CEO, Dr. Robert Preti says “since becoming part of Hitachi Chemical over a year ago, we have seen increasing interest in leveraging our PCT Global Service Platform both in the United States and Japan.” Learn about our partnership with @GSK: https://t.co/aS6Tfc9yKr
— Minaris Regenerative Medicine (@MinarisRM) October 30, 2018
#WIPOReSearch Member companies Eisai, GSK, Johnson & Johnson, and Takeda featured in November Partnership Hub Snapshot. Advancing drug discovery around #NTDs, #malaria, and #tuberculosis. https://t.co/rtLTaYv0uA@Eisai_SDGs, @GSK, @JNJGlobalHealth, @TakedaPharma, @WIPO pic.twitter.com/mnm0AJo3Ai
— BVGH (@BIOVentures) November 12, 2019
Great news that Takeda has joined the Open Targets drug discovery initiative. More here: https://t.co/XOHP4TPSpX @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/8SFnDO41B2
— Sanger Institute (@sangerinstitute) December 5, 2017
Takeda joins Open Targets drug discovery initiative. @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/XOHP4TPSpX pic.twitter.com/qPW97LuHPW
— Sanger Institute (@sangerinstitute) December 5, 2017
Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx
— Open Targets (@targetvalidate) June 21, 2019
GlaxoSmithKline, Teva, Takeda Investing in Global Sustainability Performance with the Responsible Health Initiative https://t.co/IfCIxQ9AQu via @ecovadis @GSK @Teva @tevapharmeurope @TakedaPharma @CDCGreenHealthy @bbchealth @Healthcare @HCPolicy @healthjourno1 @HCnewsEU
— EnvironmentalPartner (@MonikaWojcik) January 10, 2019
The Dementia Discovery Fund first launched in 2015 with $100 million in capital from a range of Big Pharma companies, the U.K. government and the non-profit Alzheimer's Research UK @Biogen @GSK @Johnson&Johnson @Lilly @Pfizer @Takeda @ARUK @DHSCgovukhttps://t.co/tdtENajGGx
— The Dementia Discovery Fund (@TheDDFund) August 9, 2018
236 preclinical pharma-academia #partnerships in 2015. @GSK at the top, followed by Bristol-Myers Squibb and Takeda https://t.co/ThlU1DygfF
— Giuseppe Recchia (@GGRecchia) March 26, 2016
In new best practice, 8 #pharma companies found by #AMRB2020 to have clinical-stage medicines that qualify as truly new – meaning they are more likely to remain effective for longer against resistant pathogens.https://t.co/ElTPlzfSRr@GSK @nabriva @Otsuka @scynexis @Summitplc pic.twitter.com/WtaCMcJTuA
— Access to Medicine Foundation (@AtMIndex) February 15, 2020
Did you hear? #JNJ is joining forces with @GatesFoundation, @Evotec, @GSK and Otsuka to develop a universal #TB treatment regimen. Learn how this unique collaboration builds on the #JNJ commitment to transform #TB treatment and #endTB for good ➡️ https://t.co/lJP54H0eGv pic.twitter.com/3TTCK3UHdu
— Johnson & Johnson Global Health (@JNJGlobalHealth) March 5, 2020
#WIPOReSearch Member companies Eisai, GSK, Johnson & Johnson, and Takeda featured in November Partnership Hub Snapshot. Advancing drug discovery around #NTDs, #malaria, and #tuberculosis. https://t.co/rtLTaYv0uA@Eisai_SDGs, @GSK, @JNJGlobalHealth, @TakedaPharma, @WIPO pic.twitter.com/mnm0AJo3Ai
— BVGH (@BIOVentures) November 12, 2019
On #WorldMosquitoDay, we want to thank our pharmaceutical partners for donating over seven billion life-changing treatments for #elephantiasis since 2012. #beatntds #endtheneglect @Eisai_SDGs @GSK pic.twitter.com/sYOaNgSfDE
— UnitingtoCombatNTDs (@CombatNTDs) August 20, 2020
Together with the Haitian Ministry of Health (MSPP) and our partners @GSK and @Eisai_SDGs, we are closer to eliminating a painful & disfiguring disease. #BeatNTDs
Learn more about our work in Hispaniola here: https://t.co/qFvEVXsITc pic.twitter.com/orZuiKoDGV
— The Carter Center (@CarterCenter) March 23, 2020
New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1
— Danny Edwards (@dannyjedwards) November 20, 2018
A huge thank you to our Corporate Volunteers that have been coming in to help us with maintenance and gardening around the site. Thank you to Eisai, @NatWest_Help Bishop's Stortford, '@GivingMachineUK , @GSK and @Tesco it is greatly appreciated! pic.twitter.com/fxNrSocTeO
— St Elizabeth's Centre (@St_Elizabeths) July 17, 2018
On #WorldNTDDay we celebrate our industry partnerships to #beatNTDs including the innovative Drug Discovery Booster to discover new drugs with @abbvie @AstellasUS @AstraZeneca @bmsnews @Eisai_SDGs @merckgroup Shionogi & @TakedaPharma. pic.twitter.com/j4Xgs60vO2
— Drugs for Neglected Diseases initiative (@DNDi) January 30, 2020
#NTD supply chain at #Merck attended by #Eisai, @pfizer @GSK #MSD @JNJNews @DeutschePostDHL on #schistosomiasis pic.twitter.com/ViNezXdIKC
— Merck (@merckgroup) June 28, 2016
#BreakingNews for #investors and #media: First approval of daprodustat (Duvroq) received in Japan.
— GSK (@GSK) June 29, 2020
https://twitter.com/GSK/status/1275710004411187206
https://twitter.com/GSK/status/880055699820093440
We’re partnering with @GatesFoundation, @wellcometrust & govts from Germany, Japan & Norway to #outsmartepidemics: https://t.co/vBcq9Mjy8q pic.twitter.com/wLo1DQidw6
— GSK (@GSK) January 19, 2017
.@GSK's drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas https://t.co/FMPlzKUJ69
— pharmaphorum (@pharmaphorum) June 29, 2020
Chasing #Astellas and #Mitsubishi, #GSK files for Japanese approval of oral #anemia drug https://t.co/X7cihSiIXO @FierceBiotech @GSK #daprodustat
— Plexus Ventures (@PlexusVentures) August 22, 2019
.@GSK lands 1st approval for #Duvroq as Japan greenlights drug for renal anemiahttps://t.co/ZK5FYlDf8Z $GSK pic.twitter.com/Fg8sAlJhGa
— Market Intelligence: Healthcare (@SPGMIHealthcare) June 29, 2020
GSK receives regulatory approval for Duvroq (daprodustat) in Japan in anaemia due to chronic kidney disease https://t.co/bsks1Wrmvg @GSK More Asian life science business news at [LSA] at https://t.co/BOlw85yA1L pic.twitter.com/s4Y83zBEcQ
— [iito] Life Science (@iitoLifeScience) June 29, 2020
GSK/ViiV: Dovato (dolutegravir/lamivudine), once-daily, single-pill, 2-drug regimen for HIV-1, granted marketing approval by Japan Ministry of Health, Labour and Welfare https://t.co/GF5h5nwtqV @GSK @ViiVHC More Asian life science business news at [LSA] at https://t.co/o0PHiM2bwA
— [iito] Life Science (@iitoLifeScience) January 15, 2020
Check out new #DRG epidemiology data and forecast on #herpeszoster incorporating the new #vaccine trends of #shingrix across the United States, Western Europe and Japan – live now! @DRGinsights @GSK #Shingles #VaccinesSaveLives https://t.co/r92nrjfqvg https://t.co/8zvj8CWrfZ
— DRG Epidemiology (@DRG_Epi) February 21, 2019
To take the shot or not? #DRG epidemiology report forecasts over 400 million people eligible for #influenzavaccine in 2019 across the United States, Western Europe and Japan. Check out the detailed report @DRGinsights @GSK #flu #vaccinateforlife #fluseason #Influenza https://t.co/TkI62MgvXF
— DRG Epidemiology (@DRG_Epi) January 30, 2019
Japan approval for Darzalex and Benlysta https://t.co/lCa7sYMMr4 @Genmab @JanssenGlobal @GSK #pharma
— The Pharma Letter (@ThePharmaLetter) September 27, 2017
.@GSK #SHINGRIX containing $AGEN QS-21 Stimulon® received approvals in US, Canada, and now in Europe & Japan for #prevention of #shingles in adults >=50 [https://t.co/qfmmLw3SRf]; Details here [https://t.co/Lw9n7kRgI1]. QS-21 is a part of Agenus’ neoantigen vaccine #AutoSynVax.
— Agenus Inc. ($AGEN) (@Agenus_Bio) March 26, 2018
#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC
Read: https://t.co/Ra1FDwHAXE@Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr
— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019
J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports | @AstraZeneca @JNJ @gatesfoundation @melindagates @BillGates @UniofOxford @BARDA @Sanofi @Moderna @Pfizer @BioNTech @Curevac @GSK #covid19 #vaccine #Biotech https://t.co/cRcjPrjCy9
— Aspen Biosciences (@aspenbio) July 19, 2020
On Monday, J. Sampson (@RobertWaltersJP), J. Spraggs (@GSK) and H. McLeish (@Japan_EY) kicked off the BCCJ's '#COVID19 Default to Action' webinar series.
Watch the full webinar, 'The Leadership Challenge', here: https://t.co/oix01kECMu pic.twitter.com/BhKaOagSdE
— British Chamber of Commerce in Japan (@BCCJapan) March 19, 2020
The nominees for the Diversity & Inclusion #2018BBAs are . . .
– @custommediakk
–@Freshfields Bruckhaus Deringer
– @GSK Japan
– @HoganLovells
-Intralink
– @LloydsofLondon JapanLearn more about the nominees: https://t.co/KiQHd9dQX8 pic.twitter.com/ggzYLD8Qzk
— British Chamber of Commerce in Japan (@BCCJapan) October 30, 2018